Skip to content
Clinical Evidence
PAD
PAD
DETOUR System
DETOUR System Evidence
DETOUR System Resources
DETOUR System Reimbursement
Find a Doctor
AAA
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Procedural Training
For Patients
About Us
About Us
News
The Team
Careers
External Jobs
Internal Jobs
Investigator Initiated
Research
Contact Us
Clinical Evidence
PAD
PAD
DETOUR System
DETOUR System Evidence
DETOUR System Resources
DETOUR System Reimbursement
Find a Doctor
AAA
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Procedural Training
For Patients
About Us
About Us
News
The Team
Careers
External Jobs
Internal Jobs
Investigator Initiated
Research
Contact Us
Search
Read about Endologix
in the news
Embrace the evidence.
The Latest:
Jul 9
Endologix Announces that Scott Huennekens Joins Board of Directors
See Release
All News
Archives
All
2025
2024
2023
2022
2021
Jan 29
Endologix Appoints Greg Morrow as Chief Marketing Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 15
VEITH 2017 Presentation: Status of the LEOPARD Trial: Comparing the AFX Endologix Graft to other Standard EVAR Endografts
Oct 19
Endologix Appoints John Onopchenko as Chief Operating Officer
Oct 6
Endologix Receives IDE Approval for the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix® EndoVascular Aneurysm Sealing System
Sep 21
Endologix Announces CE Mark Approval for the Nellix® EndoVascular Aneurysm Sealing System with the Refined Indications for Use
Previous
Page
1
Page
2
Page
3
Page
4
Page
5
Next
